Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00055_DB00758_nanopub.RAoMU4_ePoIDXY4DzUPxQzMgYmUAMT-fcousupILlntZU#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00055_DB00758 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00055_DB00758 label "DDI between Drotrecogin alfa and Clopidogrel - Antiplatelet agents such as clopidogrel may enhance the adverse/toxic effect of Drotrecogin Alfa. Bleeding may occur. Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents. [drugbank_resource:DB00055_DB00758]" assertion.
- drugbank_resource:DB00055_DB00758 identifier "drugbank_resource:DB00055_DB00758" assertion.
- drugbank_resource:DB00055_DB00758 title "DDI between Drotrecogin alfa and Clopidogrel - Antiplatelet agents such as clopidogrel may enhance the adverse/toxic effect of Drotrecogin Alfa. Bleeding may occur. Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents." assertion.
- drugbank:DB00055 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00055_DB00758 assertion.
- drugbank:DB00758 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00055_DB00758 assertion.